Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.68 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.68 |
| ▸ | HTR2C | P28335 | 6/20 | 0.61 |
| ▸ | GABRA1 | P14867 | 6/20 | 0.51 |
| ▸ | GABRB2 | P47870 | 5/20 | 0.51 |
| ▸ | NMT1 | P30419 | 1/20 | 0.51 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.50 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.50 |
| ▸ | HTR6 | P50406 | 1/20 | 0.50 |
| ▸ | QDPR | P09417 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4773172 | 0.98 | SLC18A3 (0.66) | SLC18A3SIGMAR1HTR2CGABRA1GABRB2 | |
| SCHEMBL12320995 | 0.89 | SLC18A3 (0.53) | SLC18A3SIGMAR1HTR2CGABRA1GABRB2 | |
| SCHEMBL27948099 | 0.86 | NPC1 (0.48) | SLC18A3SIGMAR1HTR2C | |
| SCHEMBL18903999 | 0.82 | HTR2C (0.54) | SLC18A3SIGMAR1HTR2CNMT1HTR6 | |
| SCHEMBL6373488 | 0.82 | SLC18A3 (0.76) | SLC18A3SIGMAR1HTR2CGABRA1GABRB2 | |
| SCHEMBL22051953 | 0.82 | SLC18A3 (0.76) | SLC18A3SIGMAR1HTR2CGABRA1GABRB2 | |
| SCHEMBL28928224 | 0.82 | KMO (0.49) | SLC18A3SIGMAR1 | |
| Benzene SCHEMBL28128069 | 0.82 | SLC18A3 (1.00) | SLC18A3SIGMAR1HTR2CHTR6QDPR | |
| SCHEMBL4574 | 0.82 | SLC18A3 (1.00) | SLC18A3SIGMAR1HTR2CHTR6QDPR | |
| SCHEMBL778007 | 0.81 | KMO (0.56) | SLC18A3SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250026749-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2025-01-23 | — | — | US | disclosed |
| US-12060349-B2 | Glucosylceramide synthase inhibitors | GENZYME CORPORATION (US) | 2024-08-13 | — | — | US | disclosed |
| WO-2024114672-A1 | 6,5,7,6-TETRACYCLIC DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 浙江我武翼方药业有限公司 | 2024-06-06 | — | — | WO | disclosed |
| EP-4098654-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | Genzyme Corporation (US) | 2022-12-07 | — | — | EP | disclosed |
| CN-114533729-A | Glucosylceramide synthase inhibitors | 建新公司 | 2022-05-27 | — | — | CN | disclosed |
| US-20220073508-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2022-03-10 | — | — | US | disclosed |
| EP-2895484-B1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORP (US) | 2022-02-23 | — | — | EP | disclosed |
| CN-108864076-B | Glucosylceramide synthase inhibitors | 建新公司 | 2022-02-11 | — | — | CN | disclosed |
| US-11008316-B2 | Glucosylceramide synthase inhibitors | GENZYME CORPORATION (US) | 2021-05-18 | — | — | US | disclosed |
| US-20180065957-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2018-03-08 | — | — | US | disclosed |
| WO-2014043068-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2014-03-20 | — | — | WO | disclosed |
| EP-2247600-A2 | BENZOXAZOLE CARBOXAMIDE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | Lead Therapeutics, Inc. (US) | 2010-11-10 | — | — | EP | disclosed |
| WO-2010022055-A2 | INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | AMGEN INC. (US) | 2010-02-25 | — | — | WO | disclosed |
| WO-2009099736-A2 | BENZOXAZOLE CARBOXAMIDE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | LEAD THERAPEUTICS, INC. (US) | 2009-08-13 | — | — | WO | disclosed |
| US-20080255149-A1 | Carboxyamine Compounds and Methods of Use Thereof | NOVARTIS AG | 2008-10-16 | — | — | US | disclosed |
| US-20080255149-A1 | Carboxyamine Compounds and Methods of Use Thereof | NOVARTIS AG | 2008-10-16 | — | — | US | disclosed |
| WO-2007038459-A2 | CARBOXYAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HDAC DEPENDENT DISEASES | NOVARTIS AG (CH) | 2007-04-05 | — | — | WO | disclosed |
| EP-0747357-B1 | Dihydropyridine NPY antagonists: piperidine derivatives | BRISTOL MYERS SQUIBB CO (US) | 2002-01-09 | — | — | EP | disclosed |
| US-5668151-A | USEFUL AS ANOREXIGENIC AGENTS IN PROMOTING WEIGHT LOSS AND TREATING EATING DISORDERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1997-09-16 | — | — | US | disclosed |
| EP-0747357-A2 | Dihydropyridine NPY antagonists: piperidine derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-12-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180065957-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, GBA2, GAA | SLC18A3 1931/4885SIGMAR1 4428/4885HTR2C 4831/4885 |
| US-11008316-B2 | Glucosylceramide synthase inhibitors | GBA1, GBA2, GAA | SLC18A3 2624/4885SIGMAR1 4341/4885HTR2C 4842/4885 |
| US-12060349-B2 | Glucosylceramide synthase inhibitors | GBA1, GBA2, GALC | SLC18A3 1741/4885SIGMAR1 4192/4885HTR2C 4847/4885 |
| US-20250026749-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, GBA2, GAA | SLC18A3 1931/4885SIGMAR1 4428/4885HTR2C 4831/4885 |
| US-20080255149-A1 | Carboxyamine Compounds and Methods of Use Thereof | HNMT, HDAC5, HDAC4 | SLC18A3 477/4885SIGMAR1 2655/4885HTR2C 424/4885 |
| US-20220073508-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, GBA2, GAA | SLC18A3 1931/4885SIGMAR1 4428/4885HTR2C 4831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.